x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Help - - Sign up - Phone number 902 888 740
Search

2015 FI

1.267
© Thomson Reuters, Journal Citation Reports, 2015

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect

Metrics

  • Impact Factor: 1,267(2015)
  • 5-years Impact Factor: 1,344
  • SCImago Journal Rank (SJR):0,22
  • Source Normalized Impact per Paper (SNIP):0,385
doi: 10.1016/S0025-7753(01)72044-1
Nuevos tratamientos inmunodepresores de inducción en el trasplante renal
Julio Pascual, , Joaquín Ortuño
Servicio de Nefrología. Universidad de Alcalá. Hospital Ramón y Cajal. Madrid.
Received 18 December 2000, Accepted 02 March 2001
Palabras clave
Tratamiento de inducción, Trasplante renal, Anti-IL2r, Basiliximab, Daclizumab
This article is only available in PDF
Bibliografía
1.
M.D. Denton,C.C. Magee,M.H. Sayegh
Immunosuppressive strategies in transplantation
Lancet, 353 (1999), pp. 1083-1091
2.
J. Pascual
Tratamiento inmunodepresor inicial en trasplante renal
Nefrología, 18 (1998), pp. 104-108
3.
J. Michael,G.C. Francos,J.F. Burke,A. Besarab,M. Moritiz,D. Gillum
A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients
Transplantation, 46 (1989), pp. 805-808
4.
D.P. Slakey,C.P. Johnson,R.D. Callaluce,B.J. Browne,R.Z. Yong,A.M. Roza
A prospective randomized comparison of quadruple versus triple tharapy for first cadaver transplants with immediate function
Transplantation, 56 (1993), pp. 827-831
5.
A.S. Belitsky,A.S. MacDonald,A.D. Cohen,J. Croker,D. Hirsch,K. Jindal K
Comparison of antilymphocyte globulin and continuous iv cyclosporin A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study
Transplant Proc, 23 (1991), pp. 999-1000
6.
C. Banhegyi,S. Rockenschaub,F. Muhlbacher,J. Kovarik,P. Balcke,P. Gotzinger P
Preliminary results of a prospective randomized clinical trial comparing cylosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation
Transplant Proc, 23 (1991), pp. 2207-2208
7.
D. Thibaudin,E. Alamartine,J.P. De Filippis,N. Diab,B. Laurent,F. Berthoux
Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin
Nephrol Dial Transplant, 13 (1998), pp. 711-715
8.
D.C. Brennan,K. Flavin,J.A. Lowell,T.K. Howard,S. Shenoy,S. Burgess
A randomized, double-blind comparison of thymoglobulin versus Atgam for induction immunosuppressive tharapy in adult renal transplant recipients
Transplantation, 67 (1999), pp. 1011-1018
9.
R.L. Kirkman
New usage paradigms in antibody therapy: induction or true profilaxis?
Transplant Proc, 31 (1999), pp. 1234-1235
10.
A.M. De Mattos,A.J. Olyaei,W.M. Bennett
Pharmacology of immunosuppressive medications used in renal diseases and transplantation
Am J Kidney Dis, 28 (1996), pp. 631-667
11.
D. Abramowicz,L. Schandene,M. Goldman,A. Crusiaux,P. Vereerstraeten,L. De Pauw
Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
Transplantation, 47 (1989), pp. 606-608
12.
M.R. Costanzo-Nordin
Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema and cardiac dysfunction
Transplant Proc, 25 (1993), pp. 21-24
13.
M. Goldman,D. Abramowicz,L. De Pauw,M.L. Alegre,I. Widera,P. Vereerstraeten
OKT3-induced cytokine release: attenuation by high-dose methylprednisolone
Lancet, 2 (1989), pp. 802-803
14.
B. Carpentier,C. Hiesse,C. Ferran,O. Lantz,D. Fries,J.F. Bach,L. Chatenoud
Acute clinical syndrome associated with OKT3 administration: prevention by single injection of an anti-human TNF monoclonal antibody
Presse Med, 20 (1991), pp. 2009-2011
15.
L. Schandene,C. Gerard,A. Crusiaux,D. Abramowicz,T. Velu,M. Goldman
Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline
Transplant Proc, 25 (1993), pp. 55-56
16.
C.F. Shield,L. Kahana,J. Pirsch,P. Vergne-Marini,M.R. First,T.J. Schroeder
Use of indomethacin to minimize the adverse reactions associated with Orthoclone OKT3 treatment of kidney allograft rejection
Transplantation, 54 (1992), pp. 164-165
17.
M. Alegre,K. Gastaldello,D. Abramowicz,P. Kinnaert,P. Vereerstraeten,L. De Pauw
Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome
Transplantation, 52 (1991), pp. 674-679
18.
D.J. Norman,J.A. Kimball,W.M. Bennett,F. Shihab,T.D. Batiuk,M.M. Meyer
A prospective, double-blind randomized study of high versus lowdose OKT3 induction immunosuppression in cadaveric renal transplantation
Transplant Int, 7 (1994), pp. 356-361
19.
J.P. Soulillou
Relevant targets for therapy with monoclonal antibodies in allograft tranplantation
Kidney Int, 46 (1994), pp. 540-553
20.
T. Batiuk,W.M. Bennett,M. Meyer,D.J. Norman
Cytokine nephropathy during antilymphocyte therapy
Transplant Proc, 25 (1993), pp. 27-30
21.
G.L. Chan,S.S. Weinstein,C.E. Wright,V.D. Bowers,D.Y. Alveranga,D.L. Shires
Encephalopathy associated with OKT3 administration: possible interaction with indomethacin
Transplantation, 52 (1991), pp. 148-150
22.
J.R. Thistlethwaite,J.K. Stuart,J.T. Mayes,A.O. Gaber,S. Woddle,M.R. Buckingham
Complications and monitoring of OKT3 therapy
Am J Kidney Dis, 11 (1988), pp. 112-119
23.
C.S. Oh,R.J. Stratta,B.C. Fox,H.W. Sollinger,F.O. Belzer,D.G. Maki
Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
Transplantation, 45 (1988), pp. 68-73
24.
D.W. Hanto,M.D. Jendrisak,S.K.S. So,C.S. McCullough,T.M. Rush,S.M. Michalski
Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation
Transplantation, 57 (1994), pp. 377-384
25.
E.H. Cole,D.C. Cattran,V.T. Farewell,M. Aprile,R.A. Bear,Y.P. Pei
A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection
Transplantation, 57 (1994), pp. 60-67
26.
L.J. Swinnen,M.R. Costanzo-Nordin,S.G. Fisher,E.J. O’Sullivan,M.R. Johnson,Heroux
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac- transplant recipients
N Engl J Med, 323 (1990), pp. 1723-1728
27.
G. Opelz
for the Collaborative Transplant Study. Efficacy of rejection prophylaxis with OKT3 in renal transplantation
Transplantation, 60 (1995), pp. 1220-1224
28.
L.A. Szczech,J.A. Berlin,H.I. Feldman
The effect of antilymphocyte induction therapy on renal allograft survival. A metaanalysis of individual patient data. Antilymphocyte Antibody Induction Therapy Study Group
Ann Intern Med, 128 (1998), pp. 817-826
29.
J.M. Cecka,D. Gjertson,P.I. Terasaki
Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
Transplant Proc, 25 (1993), pp. 548-549
30.
D. Abramowicz,D.J. Norman,P. Vereerstraeten,M. Goldman,L. De Pauw,J.L. Vanherweghem
OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival
Kidney Int, 49 (1996), pp. 768-772
31.
J.F. Neylan,the US Renal Transplant Mycophenolate Mofetil Study Group
Immunosuppressive therapy in high risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft patients
Transplantation, 64 (1997), pp. 1277-1282
32.
Y. Lebranchu,P. Aubert,F. Bayle,J. Bedrossian,F. Berthoux,B. Bourbigot
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One year results of a double blind, randomized, multicenter study comparing normal dose versus low dose and withdrawal of steroids
Transplant Proc, 32 (2000), pp. 396-397
33.
A.D. Hibberd,J.H. Trevillian,J.H. Wlodarzcyk,A.M. Gillies,A.M. Stein,A.G.R. Sheil
Cancer risk associated with ATG/OKT3 in renal transplantation
Transplant Proc, 31 (1999), pp. 1271-1272
34.
T.A. Waldmann
The interleukin-2 receptor
J Biol Chem, 266 (1991), pp. 2681-2684
35.
T.A. Waldmann
The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes
Science, 232 (1986), pp. 727-732
36.
T. Uchiyama,S. Broder,T.A. Waldmann
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
J Immunol, 123 (1981), pp. 1393-1397
37.
T. Uchiyama,D.L. Nelson,T.A. Fleisher,T.A. Waldmann
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
J Immunol, 126 (1981), pp. 1398-1403
38.
W.J. Leonard,J.M. Depper,G.R. Crabtree,S. Rudikoff,J. Pumphrey,R.J. Robb
Molecular cloning and expression of cDNAs for the human interleukin- 2 receptor
Nature, 311 (1984), pp. 626-631
39.
D. Cosman,D.P. Cerretti,A. Larsen,L. Park,C. March,S. Dowler
Cloning, sequence and expression of human interleukin-2 receptor
Nature, 312 (1984), pp. 768-771
40.
T. Nikaido,A. Shimizu,N. Ishida,H. Sabe,K. Teshigawara,M. Maeda
Molecular cloning of cDNA encoding human interleukin-2 receptor
Nature, 311 (1984), pp. 631-635
41.
T. Takeshita,H. Asao,K. Ohtani,N. Ishii,S. Kumaki,N. Tanaka
Cloning of the chain of the human IL-2 receptor
Science, 257 (1992), pp. 379-382
42.
J.P. Soulillou,P. Peyronnet,B. Le Mauff,M. Hourmant,D. Olive,C. Mawas
Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin-2 receptor
Lancet, 1 (1987), pp. 1339-1342
43.
J.P. Soulillou,D. Cantarovich,B. Le Mauff,M. Giral,N. Robillard,M. Hourmant
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts
N Engl J Med, 322 (1990), pp. 1175-1182
44.
M. Hourmant,B. Le Mauff,D. Cantarovich,J. Dantal,R. Baatard,M. Denis
Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody (II). Results after a second kidney transplantation
Transplantation, 57 (1994), pp. 204-207
45.
D. Cantarovich,B. Le Mauff,M. Hourmant,J. Dantal,R. Baatard,M. Denis
Prevention of acute rejection episodes with an anti-interleukin-2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation
Transplantation, 57 (1994), pp. 198-203
46.
R.L. Kirkman,M.E. Shapiro,C.B. Carpenter,D.B. McKay,E.L. Milford,E.L. Ramos
A randomized prospective trial of anti.Tac monoclonal antibody in human renal transplantation
Transplantation, 51 (1991), pp. 107-113
47.
T. Van Gelder,R. Zietse,A.H. Mulder,J.N.M. Yzermans,C.J. Hesse,L.M.B. vaessen
A double-blind, placebo-controlled study of monoclonal antiinterleukin- 2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation
Transplantation, 60 (1995), pp. 248-252
48.
P.T. Jones,P.H. Dear,J. Foote,M.S. Neuberger,G. Winter
Replacing the complementary-determining regions in a human antibody with those from a mouse
Nature, 321 (1986), pp. 522-525
49.
R.P. Junghans,T.A. Waldmann,N.F. Landolfi,N.M. Avdalovic,W.P. Schneider,C. Queen,Anti-Tac-H
a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders
Cancer Res, 50 (1990), pp. 1495-1502
50.
C. Queen,W.P. Schneider,H.E. Selick,P.W. Payne,N.F. Landolfi,J.F. Duncan
A humanized antibody that binds to the interleukin 2 receptor
Proc Natl Acad Sci USA, 86 (1989), pp. 10029-10033
51.
P.L. Amlot,E. Rawlings,O.N. Fernando,P.J. Griffin,G. Heinrich,M.H. Schreier
Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
Transplantation, 60 (1995), pp. 748-756
52.
J.M. Kovarik,E. Rawlings,P. Sweny,O. Fernando,R. Moore,P.J. Griffin
Pharmacokinetics and immunodynamics of himeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
Transplant Int, 9 (1996), pp. 32-33
53.
J. Kovarik,P. Wolf,J.M. Cisterne,G. Mourad,Y. Lebranchu,P. Lang
Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
Transplantation, 64 (1997), pp. 1701-1705
54.
J. Kovarik,M. Mentser,P. Broyer,C. Loirat,J. Crocker,G. Offner
Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients [resumen]
Transplantation, 65 (1998), pp. S66
55.
B. Nashan,R. Moore,P. Amlot,A.G. Schmidt,K. Abeywickrama,J.P. Soulillou
for the CHIB 201 International Study Group
Lancet, 350 (1997), pp. 1193-1198
56.
B.D. Kahan,P.R. Rajagopalan,M. Hall,for the United States Simulect Renal Study Group
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliimab, a chimeric antiinterleukin- 2 receptor monoclonal antibody
Transplantation, 67 (1999), pp. 276-284
57.
J. Pascual,J. García,J.J. Amenabar,M. Arias,A. Sánchez
Andrés I por el grupo de estudio de Simulect en fase IV. Basiliximab (Simulect®) disminuye significativamente la incidencia de rechazo agudo en pacientes receptores de trasplante renal que reciben terapia triple con azatioprina [resumen]
Nefrología, 20 (2000), pp. 66
58.
F. Oppenheimer,M. González-Molina,J.M. Morales,I. Andres,por el Simulect International Study Group
Basiliximab (Simulect®) es seguro y eficaz en combinación con terapia triple de Sandimmun Neoral®, esteroides y Cellcept® en pacientes receptores de trasplante renal [resumen]
Nefrología, 20 (2000), pp. 66
59.
J.E. Hartle,J.E. Bisordi,S. Chao,M.J. Freeland,J.C. West
The addition of basiliximab to cellcept, neoral and steroids resulted in a significant reduction in acute renal allograft rejection [resumen]
Transplantation, 69 (2000), pp. S159
60.
R.K. Kode,O. Pankewycz,K. Ranganna,D. Sierka,M. Ardron,A.M.S. Kumar
Rapid steroid reduction in kidney transplant recipients with Simulect, neoral and cellcept [resumen]
Transplantation, 69 (2000), pp. S224
61.
J.M. Grinyo,J.M. Cruzado,S. Gil-Vernet,D. Serón,I. Andrés
por el Grupo de Estudio Internacional de Simulect. Retirada rápida de esteroides versus una pauta de esteroides estándar en pacientes tratados con Simulect®, Sandimmun Neoral® y micofenolato mofetil para la prevención del rechazo agudo en trasplante renal [resumen]
Nefrología, 20 (2000), pp. 66
62.
H. Shidban,M. Sabawi,S. Aswad,G. Chambers,I. Castillon,R. Naraghi
Controlled trial of IL-2R antibody basiliximab (Simulect) versus low dose OKT3 in cadaver kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S156
63.
S.M. Flechner,D. Goldfarb,R. Fairchild,D. Cook,B. Mastroianni,R. Fisher
A randomized prospective trial of OKT3 vs basiliximab for induction therapy in renal transplantation [resumen]
Transplantation, 69 (2000), pp. S157
64.
R.P. Pelletier,E.A. Davies,E.A. Elkhammas,G.L. Bumgardner,M.L. Henry,R.M. Ferguson
Improved outcome in renal transplant recipients treated with Simulect versus OKT3 induction [resumen]
Transplantation, 69 (2000), pp. S157
65.
R.K. Kode,A.M.S. Kumar,O. Pankewycz,B. Fyfe,S. Stabler,K. Ranganna
Simulect induction is safer and more effective than OKT3 in kidney recipients older than 60 years [resumen]
Transplantation, 69 (2000), pp. S157
66.
S. Chowdhury,R. Kode,K. Ranganna,B. Fyfe,S. Stabler,A. Damask
Induction strategy using basiliximab combined with mycophenolate and immediate low dose cyclosporin is steroid sparing and more effective than OKT3 [resumen]
Transplantation, 69 (2000), pp. S159
67.
I. Ahmad,B. Ketel,G. Barone,Y. Barri,K. Reed,G. Almquist
Comparison of basiliimab to rabbit anti-thymocyte globulin induction in kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S159
68.
Y. Lebranchu,B. Hirault de Ligny,O. Toupance,G. Touchard,Y. Lemeur,I. Etienne
A multicenter, randomized trial of Simulect® versus Thymoglobuline ® in renal transplantation [resumen]
Tranplantation, 69 (2000), pp. S258
69.
G. Offner,M. Broyer,C. Loirat,M. Mentser,J. Lemire,J.F.S. Crocker
Multicenter study of the safety and tolerability of basiliximab (Simulect®) in de novo pediatric renal transplantation [resumen]
Transplantation, 69 (2000), pp. S258
70.
R.A. Cohn,J.R. Sherbotie,P.C. Grimm,J. Leone,R. Taylor,T. Somerville
Basiliximab (Simulect®) dramatically reduces acute rejection after pediatric kidney transplantation [resumen]
Transplantation, 69 (2000), pp. S260
71.
J. Strehlau,L. Pape,G. Offner,B. Nashan,J.H.H. Ehrich
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
Lancet, 356 (2000), pp. 1327-1328
72.
B. Philosophe,J.C. Fink,A.M. Wiland,A.C. Farney,E.J. Schweitzer,J.O. Colonna
Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function [resumen]
Transplantation, 69 (2000), pp. S259
73.
J.C. Hong,B.D. Kahan
A calcimeurin-free strategy for induction immunosuppression for delayed graft function in cadaveric kidney transplantation [resumen]
Transplantation, 69 (2000), pp. S259
74.
J.R. Thistlethwaite,B. Nashan,M. Hall,L. Chodof,T.H. Lin,on behalf of the Global Simulect Study Group
Reduced acute rejection and superior 1- year renal allograft survival with basiliximab in patients with diabetes mellitus
Transplantation, 70 (2000), pp. 784-790
75.
E.A. Elkhammas,M.L. Henry,A. Demirag,M.M. Carmona,G.L. Bumgardner,R.P. Pelletier
Basiliximab vs OKT3 in primary simultaneous pancreaskidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S407
76.
J. Odorico,E. Elkhammas,A. Secchi,P. Rigotti,K. Somberg,D. Girault
A multicenter trial of Simulect® in combination with Neoral®, Cellcept® and steroids for the prevention of acute rejection in kidney-pancreas transplantation: a low rate of rejection without recurrent diabetes mellitus [resumen]
Transplantation, 69 (2000), pp. S409
77.
J.P. Leone,R.J. Taylor
Basiliximab induction versus no induction in simultaneous kidney pancreas transplantation using mycophenolate/tacrolimus/ prednisone maintenance immunosuppression [resumen]
Transplantation, 69 (2000), pp. S410
78.
J. Hakimi,R. Chizzonite,D.R. Luke,P.C. Familletti,P. Bailon,J.A. Kondas
Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
J Immunol, 147 (1991), pp. 1352-1359
79.
P.S. Brown,G.L. Parenteau,F.M. Dirba,R.J. Garsia,C.K. Goldman,M. Bukowski
Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
Proc Natl Acad Sci USA, 88 (1991), pp. 2663-2667
80.
F. Vincenti,M. Lantz,J. Birnbaum,M. Garovoy,D. Mould,J. Hakimi
A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
Transplantation, 63 (1997), pp. 33-38
81.
F. Vincenti,R. Kirkman,S. Light,G. Bumgardner,M. Pescovitz,P. Halloran
for the Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
N Engl J Med, 338 (1998), pp. 161-165
82.
B. Nashan,S. Light,I.R. Hardie,A. Lin,J.R. Johnson,for the Daclizumab Double Therapy Study Group
Reduction of acute renal allograft rejection by daclizumab
Transplantation, 67 (1999), pp. 110-115
83.
P. Hengster,M.D. Pescovitz,D. Hyatt,R. Margreiter,on behalf of the Roche Study Group
Cytomegalovirus infections after treatment with daclizumab, an anti-IL-2 receptor antibody, for prevention of renal allograft rejection
Transplantation, 68 (1999), pp. 310-313
84.
F. Vincenti,B. Nashan,G. Bumgardner,I. Hardie,M. Pescovitz,R.W.G. Johnson,for the phase III Daclizumab Study Group
Three year outcome of the phase III clinical trials with daclizumab
Transplantation, 69 (2000), pp. S261
85.
Kirkman RL, Vincenti F, Pescovitz MD. A phase I/II randomized doubleblind placebo-controlled study of Zenapax in combination with Cellcept, Neoral and steroids. Nutley, USA: Hoffman La Roche Inc., 1998.
86.
F. Vincenti,J. Grinyo,E. Ramos,B. Nashan,F. Stuart,D. Kuypers
Can antibody prophylaxis allow sparing of other immunosuppressives
Transplant Proc, 31 (1999), pp. 1246-1248
87.
J. Lacha,M. Simova,L. Noskova,V. Teplan,S. Vitko
Zenapax versus OKT3 prophylaxis in immunologically high-risk kidney transplant recipients [resumen]
Transplantation, 69 (2000), pp. S158
88.
M.H. Deierhoi,S.L. Hudson,R.S. Gaston
Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation [resumen]
Transplantation, 69 (2000), pp. S260
89.
G.J. Chang,R. O’Rourke,I. Lee,P.G. Stock,F. Vincenti
One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function [resumen]
Transplantation, 67 (1999), pp. S149
90.
M. Millan,M. Pavlakis,E. Alfrey,O. Salvatierra,D. Dafoe,J. Scandling
A two dose regimen of daclizumab (Zenapax) in high-risk renal transplant recipients [resumen]
Transplantation, 67 (1999), pp. S84
91.
H.U. Meier-Kriesche,G.S. Friedman,S. Palekar,H. Kaza,S.P. Mulgaonkar,B. Kaplan
Daclizumab decreases acute rejection in african american and hispanic renal transplant recipients [resumen]
Transplantation, 69 (2000), pp. S156
92.
M.S. Golconda,S.C. Rayhill,L.G. Hunsicker
Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft funtion [resumen]
Transplantation, 69 (2000), pp. S158
93.
C. Siegel,J. Mead,J. Buell,A. Yoshida,K. Newell,E.S. Woodle
Comparison of daclizumab vs ATGAM induction in kidney pancreas transplantation [resumen]
Transplantation, 67 (1999), pp. S223
94.
R.J. Stratta,R.R. Alloway,E. Hodge,for the PIVOT Study Group
An open-label comparative trial of two daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: interim analysis [resumen]
Transplantation, 69 (2000), pp. S408
Correspondencia: Dr. J. Pascual. Servicio de Nefrología. Hospital Ramón y Cajal. Ctra. de Colmenar, km 9,100. 28034 Madrid.
Copyright © 2001. Elsevier España, S.L.